<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://mesowatch.org/news/2026/04/adao-epa-lawsuit-legacy-asbestos-rule/</loc>
    <news:news>
      <news:publication>
        <news:name>MesoWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-04-22T00:00:00.000Z</news:publication_date>
      <news:title>ADAO Sues EPA Over Missed Legacy Asbestos Rule Deadline</news:title>
      <news:keywords>lawsuit, verdict, legal, EPA, ADAO, legacy asbestos, TSCA, regulation, Linda Reinstein</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://mesowatch.org/images/cards/adao-epa-lawsuit-legacy-asbestos-rule-2026.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://mesowatch.org/news/2026/04/chemo-combo-trial-readouts-mesothelioma-q2-2026/</loc>
    <news:news>
      <news:publication>
        <news:name>MesoWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-04-22T00:00:00.000Z</news:publication_date>
      <news:title>Two Chemo-Combo Trials, Two Very Different Signals</news:title>
      <news:keywords>research, study, medical research, DREAM3R, durvalumab, BNT327, BioNTech, clinical trial, immunotherapy, chemotherapy</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://mesowatch.org/images/cards/chemo-combo-trial-readouts-mesothelioma-q2-2026.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://mesowatch.org/news/2026/04/orion-odm-212-fda-orphan-drug-mesothelioma/</loc>
    <news:news>
      <news:publication>
        <news:name>MesoWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-04-22T00:00:00.000Z</news:publication_date>
      <news:title>FDA Grants Orphan Drug Status to Orion&apos;s ODM-212</news:title>
      <news:keywords>research, study, medical research, ODM-212, Orion Pharma, TEAD inhibitor, Hippo pathway, FDA, orphan drug, TEADES</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://mesowatch.org/images/cards/orion-odm-212-fda-orphan-drug-mesothelioma-2026.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://mesowatch.org/news/2026/04/uk-14-toys-asbestos-recall/</loc>
    <news:news>
      <news:publication>
        <news:name>MesoWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-04-22T00:00:00.000Z</news:publication_date>
      <news:title>UK Recalls 14 Children&apos;s Toys Over Asbestos Contamination</news:title>
      <news:keywords>research, study, medical research, asbestos-exposure, product-recall, united-kingdom, consumer-safety, OPSS, tremolite</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://mesowatch.org/images/cards/uk-14-toys-asbestos-recall-2026.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://mesowatch.org/news/2026/04/v-foundation-grant-uh-cancer-center-mesothelioma/</loc>
    <news:news>
      <news:publication>
        <news:name>MesoWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-04-22T00:00:00.000Z</news:publication_date>
      <news:title>V Foundation Awards $1 Million Grant to UH Cancer Center for BAP1 Mesothelioma Research</news:title>
      <news:keywords>research, study, medical research, mesothelioma-research, bap1, genetic-testing</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://mesowatch.org/images/cards/v-foundation-1m-grant-uh-cancer-center-mesothelioma-2026.jpg</image:loc>
    </image:image>
  </url>
</urlset>